SHR 2106
Alternative Names: SHR-2106Latest Information Update: 08 Jul 2024
At a glance
- Originator Guangdong Hengrui Pharmaceutical
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Transplant rejection
Most Recent Events
- 07 Jul 2024 Preclinical trials in Transplant rejection (Prevention) in China (Parenteral), prior to July 2024 (Guangdong Hengrui Pharmaceutical pipeline, July 2024)
- 17 Jul 2023 Preclinical trials in Unspecified in China (Parenteral) (NCT05948059)
- 17 Jul 2023 Guangdong Hengrui Pharmaceutical plans a phase-I trial (In volunteers) in China (NCT05948059)